References
Key articles
National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association, and the Infectious Disease Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2024 [internet publication].Full text
The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17. Abstract
European AIDS Clinical Society. Guidelines: version 11.1 October 2022 [internet publication].Full text
Reference articles
1. Pandya R, Krentz HB, Gill MJ, et al. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci. 2005 May;32(2):201-4. Abstract
2. Wilkie FL, Goodkin K, Eisdorfer C, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):125-32. Abstract
3. Levine AJ, Hinkin CH, Ando K, et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol. 2008 Oct;30(7):836-43. Abstract
4. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 Dec 7;75(23):2087-96.Full text Abstract
5. Gray F, Chrétien F, Vallat-Decouvelaere AV, et al. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol. 2003 May;62(5):429-40. Abstract
6. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99. Abstract
7. Parsons TD, Braaten AJ, Hall CD, et al. Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes. 2006 Feb 24;4:11.Full text Abstract
8. Gibbie T, Mijch A, Ellen S, et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV Med. 2006 Mar;7(2):112-21. Abstract
9. Larussa D, Lorenzini P, Cingolani A, et al. Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. AIDS Res Hum Retroviruses. 2006 May;22(5):386-92. Abstract
10. Joska JA, Gouse H, Paul RH, et al. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol. 2010 Mar;16(2):101-14. Abstract
11. Lima VD, Geller J, Bangsberg DR, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007 May 31;21(9):1175-83. Abstract
12. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry. 2003 Aug 1;54(3):295-306. Abstract
13. Pence BW, Miller WC, Gaynes BN, et al. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):159-66. Abstract
14. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry. 2002 Jan-Feb;24(1):43-7. Abstract
15. Claypoole KH, Elliott AJ, Uldall KK, et al. Cognitive functions and complaints in HIV-1 individuals treated for depression. Appl Neuropsychol. 1998;5(2):74-84. Abstract
16. National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association, and the Infectious Disease Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2024 [internet publication].Full text
17. Blanch J, Martínez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):336-43. Abstract
18. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005 Jul-Aug;6(4):187-96. Abstract
19. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. 2010 Apr-Jun;12(2):67-75. Abstract
20. Cavalcante GI, Capistrano VL, Cavalcante FS, et al. Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci. 2010 Dec;120(12):739-45. Abstract
21. Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013 Nov;12(6):841-6. Abstract
22. Cohen CJ, Andrade-Villanueva J, Clotet B, et al; THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229-37. Abstract
23. Katlama C, Haubrich R, Lalezari J, et al; DUET-1, DUET-2 Study Groups. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009 Nov 13;23(17):2289-300. Abstract
24. Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS. 2012 Nov 28;26(18):2412-5. Abstract
25. Harris M, Larsen G, Montaner JG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008 Sep 12;22(14):1890-2. Abstract
26. Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDs. 2009 Sep;23(9):689-90. Abstract
27. Walmsley SL, Antela A, Clumeck N, et al; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18.Full text Abstract
28. Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018 Apr 24;32(7):903-12. Abstract
29. van den Berk G, Oryszczyn J, Blok W, et al. Unexpectedly high rate of intolerance for dolutegravir in real life setting. Poster 948 presented at CROI 2016. February 2016 [internet publication].Full text
30. Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS. 2008 Jul;3(4):438-45. Abstract
31. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):130-4. Abstract
32. The Mind Exchange Working Group. Assessment, diagnosis and treatment of human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND): a consensus report of the Mind Exchange Program. Clin Infect Dis. 2013 Apr;56(7):1004-17. Abstract
33. Sico JJ, Chang CC, So-Armah K, et al; Veterans Aging Cohort Study. HIV status and the risk of ischemic stroke among men. Neurology. 2015 May 12;84(19):1933-40.Full text Abstract
34. Hinkin CH, Castellon SA, Levine AJ, et al. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27(2):11-7. Abstract
35. Nelson M, Powles T, Zeitlin A, et al. Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):113-4. Abstract
36. Lortholary O, Christeff N, Casassus P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab. 1996 Feb;81(2):791-6. Abstract
37. Mayo J, Collazos J, Martínez E, et al. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med. 2002 May 27;162(10):1095-8.Full text Abstract
38. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision. Washington, DC: American Psychiatric Press; 2022.
39. McCombe JA, Auer RN, Maingat FG, et al. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology. 2009 Mar 3;72(9):835-41. Abstract
40. Chaudhuri A, Kennedy PG. Diagnosis and treatment of viral encephalitis. Postgrad Med J. 2002 Oct;78(924):575-83.Full text Abstract
41. Tang MW, Clemons KV, Katzenstein DA, et al. The cryptococcal antigen lateral flow assay: a point-of-care diagnostic at an opportune time. Crit Rev Microbiol. 2016 Aug;42(4):634-42. Abstract
42. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord. 2009 Dec;119(1-3):1-8. Abstract
43. Tan A, Yin JD, Tan LW, et al. Using the Berlin questionnaire to predict obstructive sleep apnea in the general population. J Clin Sleep Med. 2017 Mar 15;13(3):427-32.Full text Abstract
44. Gingo MR, Balasubramani GK, Rice TB, et al. Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm Med. 2014 Apr 30;14:75.Full text Abstract
45. Brew BJ, Pemberton L, Cunningham P, et al. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997 Apr;175(4):963-6. Abstract
46. Soulie C, Fourati S, Lambert-Niclot S, et al. HIV genetic distance between plasma and CSF in patients with neurological disorders. Dubrovnik, Croatia: International HIV and Hepatitis Drug Resistance Workshop; June 2010.
47. Eggers C, Hertogs K, Sturenburg HJ, et al. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS. 2003 Sep 5;17(13):1897-906. Abstract
48. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004 Sep;56(3):416-23. Abstract
49. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65-70.Full text Abstract
50. De Luca A, Ciancio BC, Larussa D, et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology. 2002 Aug 13;59(3):342-7. Abstract
51. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010 Mar 1;50(5):773-8. Abstract
52. British HIV Association. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). August 2016 [internet publication].Full text
53. Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis. 2014 Apr;58(7):1015-22.Full text Abstract
54. European AIDS Clinical Society. Guidelines: version 11.1 October 2022 [internet publication].Full text
55. Power C, Selnes OA, Grim JA, et al. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):273-8. Abstract
56. Morgan EE, Woods SP, Scott JC, et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol. 2008 Jan;30(1):83-90. Abstract
57. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010 Jun 1;24(9):1243-50. Abstract
58. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Abstract
59. Overton ET, Azad TD, Parker N, et al. The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol. 2013 Feb;19(1):109-16. Abstract
60. Brouillette MJ, Mayo N, Fellows LK, et al. A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need? AIDS. 2015 May 15;29(8):895-902.Full text Abstract
61. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007 Sep 12;21(14):1915-21. Abstract
62. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clinic Neuropsychol. 2004 May;18(2):234-48. Abstract
63. Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94(3):135-40. Abstract
64. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):111-5.Full text Abstract
65. Geldmacher H, Taube C, Kroeger C, et al. Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest. 2002 Apr;121(4):1177-82. Abstract
66. Weir MR, Thornton GF. Extrapulmonary tuberculosis. Experience of a community hospital and review of the literature. Am J Med. 1985 Oct;79(4):467-78. Abstract
67. Baydur A. The spectrum of extrapulmonary tuberculosis. West J Med. 1977 Apr;126(4):253-62.Full text Abstract
68. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection. Mar 2024 [internet publication].Full text
Use of this content is subject to our disclaimer